Icotrokinra (Icotyde): how a pill blocks IL-23 in psoriasis
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- Icotrokinra is a 13-amino-acid peptide taken as a daily tablet that blocks the receptor for interleukin-23, a driver of psoriasis. Antibodies against IL-23 work but must be injected; in 2024 its developers wrote that no oral drug selectively targeted the pathway.
- In phase 3 trials about two thirds of patients had clear or almost clear skin at week 16, against about one in ten on placebo, and the trial authors report superior response rates against the oral drug deucravacitinib.
- Very little of each dose is absorbed, which is why the label is strict: 200 mg on waking, on an empty stomach with water, then 30 minutes before food. Food cut exposure by almost half.
What icotrokinra is
The interleukin-23 (IL-23) pathway is a driver of psoriasis, psoriatic arthritis and inflammatory bowel disease 1. Monoclonal antibodies against IL-23 and IL-12 work in psoriasis, but these large proteins must be given by injection 2 3, and in 2024 icotrokinra's developers wrote that no oral therapy selectively targeted the pathway 1.
Icotrokinra takes a different route. It is a 13-amino-acid peptide, with a disulfide-bridged ring and non-natural residues, that binds the IL-23 receptor itself rather than the IL-23 protein 4, and it was stable in gastrointestinal fluids in its developers' studies 5. In laboratory studies it bound the receptor with a dissociation constant of 7.1 picomolar and blocked IL-23 signalling in human cells without affecting signalling by the related cytokine IL-12 1. FDA approved it as Icotyde on March 17, 2026 for moderate-to-severe plaque psoriasis in adults and in children aged 12 or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy, and the EU authorised it on September 18, 2026 4 6.
Why IL-23 is the target
IL-23 sits upstream of IL-17. In a rat skin-inflammation model, oral icotrokinra blocked IL-23-induced skin thickening and the induction of the IL-17A, IL-17F and IL-22 genes, and in healthy volunteers oral doses blocked IL-23 signalling in blood taken from them 1.
A 2026 meta-analysis notes that the injected route of IL-23 biologics can limit adherence and quality of life, and describes icotrokinra as a first-in-class oral peptide that antagonises the IL-23 receptor 7.
How a peptide survives being swallowed
The hard part of an oral peptide is getting any of it into the body. Icotrokinra's developers report an oral bioavailability of only 0.1% to 0.3% in animals, without any absorption enhancer, yet enough reached the bloodstream to block IL-23 signalling throughout the body 5. The molecule was stable in gastrointestinal fluids, plasma and liver cells, distributed freely to skin, joints and gut tissue, and was mostly excreted unchanged in faeces 5. The developers report systemic activity despite that low absorption 5, consistent with a drug that acts at picomolar concentrations 1.
That is a different strategy from oral semaglutide, which pairs the peptide with an absorption enhancer, and from orforglipron, approved about two weeks after icotrokinra, which is a small molecule rather than a peptide 4. Our guide to what makes a peptide a peptide explains why most peptides have to be injected. Icotrokinra shows that, for this target, a peptide built for stability and potency can work as a tablet.
What the trials showed
Icotrokinra moved from a phase 2 trial, published in February 2024, to four phase 3 trials published in 2025. The headline results at week 16 are below; 'IGA 0/1' means a dermatologist rated the skin clear or almost clear, and 'PASI 90' means at least a 90% improvement in a standard severity score 3 8 9 2:
| Trial | Who | Result at week 16 |
|---|---|---|
| FRONTIER-1 (phase 2b) | 255 adults | PASI 75 in 37% to 79% across doses vs 9% on placebo, rising with dose |
| ICONIC-LEAD (phase 3) | 684 adults and adolescents | Clear or almost clear skin (IGA 0/1) 65% vs 8%; PASI 90 50% vs 4%; completely clear (IGA 0) 33% vs 1% |
| ICONIC-TOTAL (phase 3) | 311 with scalp, genital or hand and foot psoriasis | IGA 0/1 56.7% vs 5.8%; scalp 65.9% vs 10.6%; genital 76.5% vs 21.4%; hand and foot 41.7% vs 26.1% (not significant) |
| ICONIC-ADVANCE 1 (phase 3) | 774 adults, with a deucravacitinib arm | IGA 0/1 68% vs 11% on placebo; PASI 90 55% vs 4% |
| ICONIC-ADVANCE 2 (phase 3) | 731 adults, with a deucravacitinib arm | IGA 0/1 70% vs 9% on placebo; PASI 90 57% vs 1% |
Three points stand out. Responses were dose-dependent in phase 2 3. The phase 3 programme included adolescents 8 and people with psoriasis on the scalp and genitals, places that are hard to treat and matter a great deal to patients, though the hand-and-foot result missed significance 9. And in ICONIC-ADVANCE, whose coprimary endpoints were against placebo, the authors report superior response rates against both placebo and deucravacitinib, an approved oral psoriasis drug, with fewer adverse events by week 24 (57% against 65%) 2. A 2026 meta-analysis of the five randomised trials (one phase 2, four phase 3) found icotrokinra about seven times as likely as placebo to produce clear or almost clear skin at week 16, with no heterogeneity between trials 7.
The phase 2 trial that made the case
The first large test, FRONTIER-1, enrolled 255 adults with a mean severity score of 19.1 and psoriasis for an average of 18 years; 78% had already tried systemic treatment. Across five dose groups, the share reaching a 75% improvement in severity at week 16 rose steadily with dose, from 37% to 79%, against 9% on placebo, and the share with at least one adverse event was similar to placebo (52% against 51%) 3. The dose-response was statistically significant 3.
Does it last?
Psoriasis is lifelong, so durability matters. In the phase 2 extension, response rates were maintained from week 16 to week 52, with 74% clear or almost clear at a year on the highest dose 10. In a one-year durability analysis reported in 2026, about 70% to 75% of patients randomised to icotrokinra had clear or almost clear skin during weeks 24 to 52, and 85% to 90% of week-16 responders kept their response at week 52 11. Longer data will be needed; the ICONIC-LEAD authors say the same 8.
Safety and the label
Across the trials, adverse event rates were similar to placebo; the most common were nasopharyngitis and upper respiratory infections 8 2. A pooled safety analysis through one year, covering 1,840 participant-years, found adverse events, serious adverse events, infections and discontinuations comparable to placebo through week 16 12. The label carries three warnings: infections, tuberculosis and immunizations. It advises considering a tuberculosis evaluation before treatment, completing vaccinations according to current guidelines first and avoiding live vaccines during treatment, noting that medicines that interact with the immune system may increase the risk of infection 6.
The dosing instructions follow from the absorption problem. The label dose is 200 mg once daily, taken on waking on an empty stomach with water, waiting at least 30 minutes before eating; taking it with food cut total exposure by 43% and peak concentration by 59%, and steady state is reached in about three days 6. The tablet is swallowed whole, and it can be dispersed in water for people who cannot swallow it 6. These instructions come from the label and are reproduced here for information, not as advice.
What happens after the tablet
The label describes a drug that behaves predictably once it is absorbed. After a 200 mg dose, blood levels peak at a median of about two hours, though anywhere from 15 minutes to 8 hours; exposure rises in proportion to dose across a wide range; and with daily dosing, levels build up by up to 1.5- to 1.6-fold and reach a steady state in about three days 6. Its median elimination half-life is 12 hours 6. Its pharmacokinetics were similar in healthy volunteers and in people with psoriasis 6.
Because it is a peptide rather than a conventional small molecule, it does not appear to tangle with the liver enzymes and transporters behind many drug interactions: in the developers' studies it was neither a substrate nor an inhibitor of prototypical cytochrome P450 enzymes or drug transporters, and they identified no risk of drug interactions from in vitro studies 5. Any combination should still be checked with a pharmacist.
A pill or an injection?
For patients, the choice between icotrokinra and an injected IL-23 or IL-17 drug will turn on more than skin clearance. A daily tablet avoids needles but has to be taken every morning, on an empty stomach, at least 30 minutes before food; taking it with a high-fat meal lowered exposure by 43% 6. Icotrokinra's pooled safety record so far runs to about a year 12.
No published randomised trial has yet compared icotrokinra directly with an injected IL-23 antibody, so claims that it matches them rest on comparisons across separate trials, which differ in their patients and methods. Its published direct comparisons so far are with placebo and with deucravacitinib 2; a phase 3 trial with an arm on ustekinumab, an injected antibody against IL-12 and IL-23, is registered (NCT06934226, active, not recruiting) 13. Which treatment suits a given patient is a decision for them and their dermatologist, weighing response, convenience, cost and other health conditions.
What it means for oral peptides
Icotrokinra matters beyond psoriasis because it shows that a peptide can be engineered to work as an ordinary daily tablet against a pathway previously reached by injected antibodies 7 2. It was followed in July 2026 by enlicitide, an oral macrocyclic peptide that blocks PCSK9 to lower cholesterol, another target previously served by injections 4. Together they mark a shift that our 2026 pipeline overview describes in more detail. Icotrokinra is also in phase 3 trials in psoriatic arthritis, and in phase 2b/3 or phase 3 trials in Crohn's disease and ulcerative colitis 13.
None of this applies to research peptides sold online. Icotrokinra's absorption, stability and blood levels were measured in its developers' studies and on its label 5 6; our guide to oral peptides found no published human study measuring absorption of research peptides sold in capsules.
Frequently asked questions
What is Icotyde?
Icotyde is the brand name for icotrokinra, a once-daily oral peptide that blocks the interleukin-23 receptor. FDA approved it on March 17, 2026 for moderate-to-severe plaque psoriasis in adults and children 12 and older weighing at least 40 kg.
How well does icotrokinra work?
In phase 3 trials, 65% to 70% of patients had clear or almost clear skin at week 16, against 8% to 11% on placebo, and the ICONIC-ADVANCE authors report superior response rates against deucravacitinib.
How do you take Icotyde?
The label says 200 mg once daily on waking, on an empty stomach with water, waiting at least 30 minutes before eating, because food reduces absorption.
Is icotrokinra a biologic?
No. It is a 13-amino-acid peptide, far smaller than the antibodies that block IL-23, and it is taken by mouth rather than injected.
Related on Grey Peptides
Sources
- Fourie, A. M., et al. (2024). JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep, 14(1), 17515. PMID: 39080319
- Gold, L. S., et al. (2025). Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet, 406(10510), 1363-1374. PMID: 40976249
- Bissonnette, R., et al. (2024). An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. N Engl J Med, 390(6), 510-521. PMID: 38324484
- Grey Peptides encyclopedia entries for icotrokinra (approval details, NDA 220149; EU authorisation; sequence description), enlicitide, oral semaglutide and orforglipron. Read October 27, 2026.
- Knight, B., et al. (2025). Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling. Dermatol Ther (Heidelb), 15(9), 2495-2520. PMID: 40629250
- Janssen Biotech. Icotyde (icotrokinra) tablets, US prescribing information, sections 1, 2, 5 and 12.3 (DailyMed set aee3c963, version 2, effective March 17, 2026; still current October 27, 2026). Read October 27, 2026. DailyMed
- Advani, S., et al. (2026). Efficacy and Safety of Icotrokinra for Plaque Psoriasis: A Systematic Review and Meta-analysis. Clin Exp Dermatol, . PMID: 42308521
- Bissonnette, R., et al. (2025). Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. N Engl J Med, 393(18), 1784-1795. PMID: 41191940
- Gooderham, M., et al. (2025). Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. NEJM Evid, 4(12), EVIDoa2500155. PMID: 41191932
- Ferris, L. K., et al. (2025). FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol, 92(3), 495-502. PMID: 39549848
- Stein Gold, L., et al. (2026). Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials. Br J Dermatol, 195(4), 600. PMID: 42397072
- Lebwohl, M. G., et al. (2026). Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials. Dermatol Ther (Heidelb), . PMID: 42663861
- ClinicalTrials.gov search for icotrokinra or JNJ-77242113, October 27, 2026: phase 3 trials in psoriatic arthritis (NCT06807424, NCT06878404), a phase 2b/3 trial in Crohn's disease (NCT07196722), a phase 3 trial in ulcerative colitis (NCT07196748), and a phase 3 plaque psoriasis trial with an ustekinumab active comparator (NCT06934226, active, not recruiting).
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead